CL2022000374A1 - Métodos para preparar análogos de incretina - Google Patents

Métodos para preparar análogos de incretina

Info

Publication number
CL2022000374A1
CL2022000374A1 CL2022000374A CL2022000374A CL2022000374A1 CL 2022000374 A1 CL2022000374 A1 CL 2022000374A1 CL 2022000374 A CL2022000374 A CL 2022000374A CL 2022000374 A CL2022000374 A CL 2022000374A CL 2022000374 A1 CL2022000374 A1 CL 2022000374A1
Authority
CL
Chile
Prior art keywords
preparing
methods
incretin
analogues
incretin analogues
Prior art date
Application number
CL2022000374A
Other languages
English (en)
Inventor
Michael E Kopach
Sergey Vladimirovich Tsukanov
Yu Lu
Timothy Donald White
Ankur Jalan
Jinju James
Michael E Kobierski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2022000374A1 publication Critical patent/CL2022000374A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen compuestos intermediarios para preparar análogos de incretina o sales farmacéuticamente aceptables de estos. Además, se describen métodos para preparar análogos de incretina mediante el acoplamiento de dos a cuatro de los compuestos intermediarios de la presente descripción mediante síntesis en fase híbrida sólida líquida o unión química nativa.
CL2022000374A 2019-08-19 2022-02-15 Métodos para preparar análogos de incretina CL2022000374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962888756P 2019-08-19 2019-08-19

Publications (1)

Publication Number Publication Date
CL2022000374A1 true CL2022000374A1 (es) 2022-11-18

Family

ID=72322545

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000374A CL2022000374A1 (es) 2019-08-19 2022-02-15 Métodos para preparar análogos de incretina

Country Status (15)

Country Link
US (1) US20220411461A1 (es)
EP (1) EP4017866A1 (es)
JP (1) JP2022545200A (es)
KR (1) KR20220035199A (es)
CN (1) CN114269775A (es)
AU (1) AU2020334993B2 (es)
BR (1) BR112022001081A2 (es)
CA (1) CA3148347A1 (es)
CL (1) CL2022000374A1 (es)
CO (1) CO2022001413A2 (es)
EC (1) ECSP22013340A (es)
IL (1) IL289957A (es)
MX (1) MX2022002115A (es)
PE (1) PE20221049A1 (es)
WO (1) WO2021034815A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710462A (zh) 2021-01-20 2023-09-05 维京治疗公司 用于治疗代谢病症和肝病的组合物和方法
WO2022235991A1 (en) 2021-05-07 2022-11-10 Eli Lilly And Company Erodible tablet
TW202404996A (zh) * 2022-04-04 2024-02-01 美商美國禮來大藥廠 製備glp-1/升糖素雙重促效劑之方法
CN115368234B (zh) * 2022-08-19 2024-01-26 淄博矿业集团有限责任公司 一种索马鲁肽侧链及其中间体的合成方法
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046349A1 (en) 2009-07-15 2011-02-24 Matthieu Giraud Process for the production of exenatide and of an exenatide analogue
CN104470948B (zh) 2012-05-03 2018-06-15 西兰制药公司 Gip-glp-1双激动剂化合物及方法
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
ES2900744T3 (es) * 2013-05-28 2022-03-18 Takeda Pharmaceuticals Co Compuesto de péptidos
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
CN103613656B (zh) * 2013-11-20 2015-03-04 陕西东大生化科技有限责任公司 一种艾塞那肽的固相片段合成方法
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
MX2018008027A (es) 2015-12-31 2018-11-29 Hanmi Pharm Ind Co Ltd Activador triple que activa receptor de glucagon, glp-1 y gip.
BR112018067731A2 (pt) 2016-03-10 2019-01-08 Medimmune Ltd coagonistas de glucagon e glp-1 para o tratamento de obesidade
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CN106749610A (zh) * 2016-12-29 2017-05-31 陕西慧康生物科技有限责任公司 一种艾塞那肽的制备方法及其产品
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US11084861B2 (en) 2018-07-23 2021-08-10 Eli Lilly And Company GIP/GLP1 co-agonist compounds

Also Published As

Publication number Publication date
US20220411461A1 (en) 2022-12-29
CA3148347A1 (en) 2021-02-25
AU2020334993B2 (en) 2023-07-13
WO2021034815A1 (en) 2021-02-25
CN114269775A (zh) 2022-04-01
MX2022002115A (es) 2022-03-17
AU2020334993A1 (en) 2022-02-24
PE20221049A1 (es) 2022-06-30
IL289957A (en) 2022-03-01
EP4017866A1 (en) 2022-06-29
KR20220035199A (ko) 2022-03-21
BR112022001081A2 (pt) 2022-05-24
JP2022545200A (ja) 2022-10-26
ECSP22013340A (es) 2022-03-31
CO2022001413A2 (es) 2022-03-18

Similar Documents

Publication Publication Date Title
CL2022000374A1 (es) Métodos para preparar análogos de incretina
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
AR118856A2 (es) Compuestos terapéuticos
UY32490A (es) Inhibidores de beta-secretasa
CR20120460A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
GT201300207A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
UY35263A (es) Compuestos terapéuticos
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
BR112015021596A2 (pt) moduladores de gpr120 de ácido oxabiciclo[2.2.2]
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
PE20130228A1 (es) Heterociclilbencilpirazoles sustituidos
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
CY1121147T1 (el) Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου
BR112016013618A8 (pt) derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
IN2014MN00971A (es)
CU20200047A7 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
AR090959A1 (es) Analogos de hexadepsipeptidos como compuestos anticancerigenos
CO2019012592A2 (es) Proceso para la preparacion de piperazina para la síntesis de derivados de pirazinocarbazol